EG23909A - Vatamin d, analogs - Google Patents

Vatamin d, analogs

Info

Publication number
EG23909A
EG23909A EG20000872A EG20000872A EG23909A EG 23909 A EG23909 A EG 23909A EG 20000872 A EG20000872 A EG 20000872A EG 20000872 A EG20000872 A EG 20000872A EG 23909 A EG23909 A EG 23909A
Authority
EG
Egypt
Prior art keywords
vatamin
analogs
Prior art date
Application number
EG20000872A
Other languages
English (en)
Inventor
Andrew D Batcho
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of EG23909A publication Critical patent/EG23909A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C401/00—Irradiation products of cholesterol or its derivatives; Vitamin D derivatives, 9,10-seco cyclopenta[a]phenanthrene or analogues obtained by chemical preparation without irradiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EG20000872A 1999-07-12 2000-07-04 Vatamin d, analogs EG23909A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14341399P 1999-07-12 1999-07-12

Publications (1)

Publication Number Publication Date
EG23909A true EG23909A (en) 2007-12-30

Family

ID=22503954

Family Applications (1)

Application Number Title Priority Date Filing Date
EG20000872A EG23909A (en) 1999-07-12 2000-07-04 Vatamin d, analogs

Country Status (36)

Country Link
US (1) US6331642B1 (es)
EP (1) EP1200399B1 (es)
JP (1) JP3803579B2 (es)
KR (1) KR100477161B1 (es)
CN (1) CN1174964C (es)
AR (1) AR024695A1 (es)
AT (1) ATE262508T1 (es)
AU (1) AU779408B2 (es)
BR (1) BR0012419A (es)
CA (1) CA2378803C (es)
CO (1) CO5190683A1 (es)
DE (1) DE60009303T2 (es)
DK (1) DK1200399T3 (es)
EG (1) EG23909A (es)
ES (1) ES2215707T3 (es)
GC (1) GC0000198A (es)
HK (1) HK1047578B (es)
HR (1) HRP20020007A2 (es)
HU (1) HUP0202157A3 (es)
IL (2) IL147254A0 (es)
JO (1) JO2255B1 (es)
MA (1) MA26808A1 (es)
MX (1) MXPA02000313A (es)
MY (1) MY122633A (es)
NO (1) NO20020161D0 (es)
NZ (1) NZ516339A (es)
PE (1) PE20010328A1 (es)
PL (1) PL201877B1 (es)
PT (1) PT1200399E (es)
RS (1) RS50229B (es)
RU (1) RU2235721C2 (es)
TR (1) TR200200054T2 (es)
TW (1) TWI268276B (es)
UY (1) UY26239A1 (es)
WO (1) WO2001004089A1 (es)
ZA (1) ZA200110487B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001278744A1 (en) * 2000-08-17 2002-02-25 Chugai Seiyaku Kabushiki Kaisha Remedial agent for osteoporosis
DE60121986T2 (de) 2000-10-02 2007-07-26 Emory University Triptpolidanaloge zur verendung in der behandlung von autoimmunbedingten und entzündlichen erkrankungen
AU2002338672B2 (en) * 2001-09-21 2006-03-09 F. Hoffmann-La Roche Ag 3-desoxy-vitamin D3 analog esters
US7563810B2 (en) 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
US8034831B2 (en) 2002-11-06 2011-10-11 Celgene Corporation Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
JP2006525367A (ja) * 2003-04-30 2006-11-09 ビオクセル エッセ ピ ア ジェミニビタミンｄ３化合物及びその使用方法
US20050113348A1 (en) * 2003-06-12 2005-05-26 Yanchun Li Vitamin D and vitamin D analogs or derivatives as new anti-hypertensive agents
GB2407499B (en) * 2003-11-03 2008-02-27 Bioxell Spa Vitamin D3 analogue for use in the treatment of BPH
PT103177A (pt) * 2003-09-24 2005-03-31 Bioxell Spa 1-alfa-fluoro-25-hidroxi-16,23e-dieno-26,27-bis-homo-20-epi-colecalciferol, seus sais ou esteres e sua utilizacao no fabrico de medicamentos
US20070054887A1 (en) * 2003-09-24 2007-03-08 Bioxell S.P.A Methods for treating bladder dysfunction
US8404667B2 (en) * 2006-12-29 2013-03-26 Wisconsin Alumni Research Foundation Compounds, compositions, kits and methods of use to orally and topically treat acne and other skin conditions by 19-Nor vitamin D analog
JP2008514621A (ja) * 2004-09-24 2008-05-08 ビオクセル エッセ ピ ア ２０−シクロアルキル，２６，２７−アルキル／ハロアルキル−ビタミンｄ３化合物及びその使用方法
US20080293647A1 (en) 2004-11-12 2008-11-27 Luciano Adorini Combined Use Of Vitamin D Derivatives And Anti-Proliferative Agents For Treating Bladder Cancer
US20100009949A1 (en) * 2006-03-24 2010-01-14 Bioxell S.P.A. Novel method
EP2167516B1 (en) * 2007-05-30 2015-07-22 Opko IP Holdings II, Inc. Process for producing phosphine oxide vitamin d precursors
EP3521311A1 (en) 2008-04-11 2019-08-07 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
US9018194B2 (en) * 2011-03-02 2015-04-28 Nibon University Vitamin D receptor modulators with partial agonist activity
KR102523660B1 (ko) 2016-09-26 2023-04-19 (주)하이플 박스용 테두리 부재보강부재와 에셈블리컨테이너 원터치크립이 포함된 박스

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4749710A (en) 1985-05-01 1988-06-07 Hoffmann-La Roche Inc. Immunosuppressive agents
US5087619A (en) * 1988-01-20 1992-02-11 Hoffman-La Roche Inc. Vitamin D3 analogs
ZA8923B (en) * 1988-01-20 1989-09-27 Hoffmann La Roche 16-dehydro-vitamin d3-derivatives
CA2096105A1 (en) * 1992-10-07 1994-04-08 Enrico Giuseppe Baggiolini (Deceased) Vitamin d3 fluorinated analogs
US5401733A (en) * 1993-10-01 1995-03-28 Hoffmann-La Roche Inc. Stable and active metabolites of 1,25-dihydroxy-16-ene-cholecalciferol
US5428029A (en) * 1993-11-24 1995-06-27 Hoffmann-La Roche Inc. Vitamin D3 fluorinated analogs
US6040300A (en) * 1995-04-07 2000-03-21 Arch Development Corporation Method of preventing colon cancer with vitamin D3 analogues
AU708679B2 (en) 1996-03-21 1999-08-12 F. Hoffmann-La Roche Ag 1,25-dihydroxy-16,22,23-trisdehydro-cholecalciferol derivatives

Also Published As

Publication number Publication date
EP1200399B1 (en) 2004-03-24
TWI268276B (en) 2006-12-11
NO20020161L (no) 2002-01-11
RU2235721C2 (ru) 2004-09-10
YU92701A (sh) 2004-09-03
HUP0202157A2 (en) 2002-10-28
HK1047578B (zh) 2005-04-29
PL356124A1 (en) 2004-06-14
ATE262508T1 (de) 2004-04-15
DE60009303D1 (de) 2004-04-29
JP2003504354A (ja) 2003-02-04
CN1174964C (zh) 2004-11-10
GC0000198A (en) 2006-03-29
HK1047578A1 (en) 2003-02-28
UY26239A1 (es) 2000-10-31
WO2001004089A1 (en) 2001-01-18
ES2215707T3 (es) 2004-10-16
MA26808A1 (fr) 2004-12-20
PL201877B1 (pl) 2009-05-29
IL147254A (en) 2006-07-05
DK1200399T3 (da) 2004-07-19
EP1200399A1 (en) 2002-05-02
PT1200399E (pt) 2004-06-30
BR0012419A (pt) 2002-03-26
MY122633A (en) 2006-04-29
NZ516339A (en) 2003-07-25
CA2378803C (en) 2009-01-27
MXPA02000313A (es) 2002-06-21
CO5190683A1 (es) 2002-08-29
ZA200110487B (en) 2003-03-20
AR024695A1 (es) 2002-10-23
PE20010328A1 (es) 2001-03-22
NO20020161D0 (no) 2002-01-11
IL147254A0 (en) 2002-08-14
KR20020033728A (ko) 2002-05-07
RS50229B (sr) 2009-07-15
US6331642B1 (en) 2001-12-18
AU779408B2 (en) 2005-01-20
HRP20020007A2 (en) 2003-04-30
AU6689400A (en) 2001-01-30
DE60009303T2 (de) 2005-02-24
TR200200054T2 (tr) 2002-06-21
JO2255B1 (en) 2004-10-07
KR100477161B1 (ko) 2005-03-18
CA2378803A1 (en) 2001-01-18
CN1360572A (zh) 2002-07-24
HUP0202157A3 (en) 2004-04-28
JP3803579B2 (ja) 2006-08-02

Similar Documents

Publication Publication Date Title
MXPA01013362A (es) Anticuerpos de humano, anti-alfavbeta3 recombinantes, °cidos nucleicos que codifican a los mismos y metodos de uso.
GB0029386D0 (en) Not known at present
ZA200200477B (en) 2-pyrazolin-5-ones.
HK1054384A1 (en) 4-Pyrimidinyl-n-acyl-l-phenylalanines.
ZA200202537B (en) Pour-on-formulations.
GB0029389D0 (en) Not known at present
ZA200201829B (en) New phenylpiperazines.
ZA200203762B (en) 4-pyridinyl-IN-acyl-L-phenylalanines.
ZA200108968B (en) New compounds.
EG23909A (en) Vatamin d, analogs
MXPA02000261A (es) Aminoindanos novedosos.
HK1048307A1 (zh) 取代的雜環基-2h-苯並吡喃類化合物
GB0029720D0 (en) I.S machine7544232001
GB9913742D0 (en) Horologe improvement
AU6550800A (en) Hepoxilin analogs
GB9911456D0 (en) Oligohydroxyl substituted 3-urea-benzofurane-and-pyridofurane-derivatives
PL352101A1 (en) Substituted phenylcyclohexanocarboxyamides
ZA200204581B (en) Nitro-sulfobenzamides.
GB9903377D0 (en) Amphibious-tricycle (amphi-trike)
HK1031254A1 (en) Tachogragh.
ZA200201714B (en) Novel compound F-15078.
GB0027081D0 (en) Solution
TW433433U (en) Improved lampstand
GB9925815D0 (en) Divided sauce-pan
HU0500936D0 (en) Polimeric hydroxylamine- and alpha, betha-unsatured alkenoate-resins